Therefore, in terms of application, our data suggest that a new molecular classification based on the mutational status of CD79B and PIM1 could be used to predict patient outcomes in CNS DLBCL. This evidence concerns the gene PIM1 and diffuse large B-cell lymphoma of the central nervous system.